Vertex to present data highlighting long-term benefits of trikafta® at the north american cystic fibrosis conference

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that data on trikafta® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), which can treat the underlying cause of cystic fibrosis (cf) in ~90% of people with the disease, will be presented at the 2023 north american cystic fibrosis conference (nacfc) taking place november 2-4, 2023 in phoenix, arizona. presentations will highlight results from two open-label extension studies demonstrating the long-term c.
VRTX Ratings Summary
VRTX Quant Ranking